Nicole Hernandez Cordero, MD
Endocrinology, Diabetes & Metabolism · Bayamon, PRNPI 1861947137
Payments from drug & device makers
Across 172 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$947
- Dexcom, Inc.$754
- Novo Nordisk$447
- Amgen$446
- AstraZeneca$375
- Sanofi-aventis U.S. LLC$318
- plus $958 from 11 others
What the payments were for
- Food & beverage$4,18098%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 24 | $947 |
| Dexcom, Inc. | 44 | $754 |
| Novo Nordisk | 23 | $447 |
| Amgen(2 entities) | 8 | $446 |
| AstraZeneca | 17 | $375 |
| Sanofi-aventis U.S. LLC | 15 | $318 |
| PBG Puerto Rico LLC | 13 | $270 |
| Merck | 9 | $160 |
| Medtronic | 4 | $121 |
| Lilly USA, LLC | 1 | $119 |
| Johnson & Johnson | 5 | $112 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $78 |
| AbbVie | 2 | $36 |
| Novartis | 1 | $18 |
| Bayer Puerto Rico Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$463
- DEXCOM G7 GSS (161)$242
- Repatha$125
- FARXIGA$125
- DEXCOM STELO GLUCOSE BIOSENSOR$121
- ZEPBOUND$119
- TEPEZZA$119
- DEXCOM G6 TRANSMITTER$113
- SYNJARDY$112
- TRIJARDY XR$112
How this compares
$4,245 in reported general payments places this provider in the 40th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 314 | $310,479 |
| JardianceEmpagliflozin | 300 | $238,124 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 235 | $162,464 |
| TrulicityDulaglutide | 127 | $128,902 |
| FarxigaDapagliflozin Propanediol | 128 | $92,661 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 90 | $59,881 |
| MounjaroTirzepatide | 54 | $59,397 |
| JanuviaSitagliptin Phosphate | 60 | $59,312 |
| SynthroidLevothyroxine Sodium | 804 | $57,173 |
| SynjardyEmpagliflozin/Metformin Hcl | 68 | $52,550 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 78 | $48,725 |
| TradjentaLinagliptin | 65 | $41,563 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $31,782 |
| ProliaDenosumab | 17 | $30,057 |
| GlyxambiEmpagliflozin/Linagliptin | 34 | $24,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy, Tradjenta | $947 | $607,433835 claims |
| Novo NordiskOzempic, Rybelsus | $447 | $328,116332 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Humulin N | $119 | $213,499352 claims |
| MerckJanuvia, Janumet Xr | $160 | $108,037138 claims |
| AstraZenecaFarxiga | $375 | $92,661128 claims |
| AbbVieSynthroid | $36 | $57,173804 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $318 | $50,377244 claims |
| AmgenProlia | $446 | $30,05717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Bayamon
- Angel Comulada RiveraBayamon$8.9M
- Paola Mansilla-LetelierBayamon$3.1M
- Altagracia Alcantara GonzalezBayamon$1M
- Jean Pujals KuryBayamon$50K
- Gloria Vega CarattiniBayamon$26K
- Hiram Maldonado RiveraBayamon$7K
- Ramon Ortiz CarrasquilloManati$6M
- Alex Gonzalez BossoloSan Juan$5.5M
- Martha GomezSan Juan$3.8M
- Myriam Allende-VigoHumacao$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.